Dr. Lal Pathlabs Ltd. share price target

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Company has 216 clinical laboratories, including National Reference Lab at Delhi and Regional...

The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...

We remain negative on the entire diagnostic chain with a belief of 1) premium players losing their market share to unorganized players, 2) B2B (40% of revenue) partners negotiating to partially offset their loss of profit, 3) Inability to hike prices causing lower realization level (Revenue/Patient) and 4) higher fixed costs (60-65% of operating cost for DLPL), new compliance expense and home collection of samples will lead to lower EBITDA margin. However even after increased estimate, we maintain SELL' recommendation but revised TP to Rs1,006 (from Rs895) on PE 40x of FY22E due to challenging...

28-30% of revenue compared to last year in Q1FY21E and gradual recovery from Q2FY21E. As per the management, 60-65% of DLPL's total operating cost is fixed in nature and the new additional expense (cost of safety for...

DLPL's strong business model led to a revenue growth of 16.2% CAGR over FY15-19, supported by rise in sample collection (~18.6% CAGR; backed by large network of PSCs 1,600 and PUPs) along with growing number of patient served (+15.5% CAGR). Company's 1,200 Hub and Spoke model (centralized diagnostic testing) offers economies of scale and 800...

Dr Lal PathLabs (DLPL) Q1FY20 earnings came marginally higher than our estimates on account of improved revenue contribution from regions constituting

DLPL's revenue, adj. EBITDA and PAT grew 15%, 21% and 19% YoY Change in Estimates | Target | Reco With strong cash flow and growth in new customers and packaged offer, the...

DLPL's revenue, adj. EBITDA and PAT grew 11%, 16% and 27% YoY Change in Estimates | Target | Reco respectively in Q3FY19 and in line with our estimates in margin and earnings. With strong cash flow and growth in new customers and packaged offer, the...

Revenue grew by 5.99% to Rs. 219.9 Cr in Q4FY17 when compared to the previous quarter

growth from ~ 12.0 mn in FY16 to ~ 13.3 mn in FY17 as well as a better sales mix, resulting in improvement in realizations per patient from 660 in FY16 to 688 in FY17. While H1FY17 saw the company's revenues expand at a faster pace where it registered a...